Genmab A/S (GNMSF)
OTC
Real-time Data
01:30 PM
Day's Range
275.7952 wk Range
208.80Overview - GNMSF - Genmab A/S
Key Statistics
Valuation
Enterprise Value
23.88B
P/E (Trailing)
‪26.66‬
P/E (Forward)
‪24.38‬
PEG Ratio
‪-2.90‬
Price / Sales (TTM)
‪5.01‬
Price / Book
‪3.64‬
EV / EBITDA
‪17.34‬
Profitability
Gross Margin
‪92.72%‬
Profit Margin
‪19.07%‬
Operating Margin
‪35.23%‬
Return on Assets
‪8.78%‬
Return on Equity
‪13.99%‬
Ownership
Shares Outstanding
62.35M
Float
58.96M
Held by Insiders
‪0.00%‬
Held by Institutions
‪40.02%‬
Price stats
Beta
‪0.68‬
50-Day Avg
‪283.59‬
200-Day Avg
‪290.75‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - GNMSF - Genmab A/S
Peer Comparison
Compared with companies in Biotechnology listed on OTC.
Profile Summary - GNMSF - Genmab A/S
About
Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics primarily for cancer and other serious diseases. Founded in 1998, it focuses on innovative human antibody technologies to create differentiated products that address…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
